Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. more
Dec '22 | Dec '23 | |||||
---|---|---|---|---|---|---|
Total Revenue | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Cost of Revenue | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Gross Profit | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Gross Margin | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Operating Expenses | 29.77M | 36.93M | [{"date":"2022-12-31","value":80.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |||
Operating Income | (29.77M) | (36.93M) | [{"date":"2022-12-31","value":-2976600000,"profit":false},{"date":"2023-12-31","value":-3693400000,"profit":false}] | |||
Total Non-Operating Income/Expense | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Pre-Tax Income | (29.51M) | (35.31M) | [{"date":"2022-12-31","value":-2951200000,"profit":false},{"date":"2023-12-31","value":-3531100000,"profit":false}] | |||
Income Taxes | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Income After Taxes | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Income From Continuous Operations | (29.51M) | (35.31M) | [{"date":"2022-12-31","value":-2951200000,"profit":false},{"date":"2023-12-31","value":-3531100000,"profit":false}] | |||
Income From Discontinued Operations | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |||
Net Income | (29.51M) | (35.31M) | [{"date":"2022-12-31","value":-2951200000,"profit":false},{"date":"2023-12-31","value":-3531100000,"profit":false}] | |||
EPS (Diluted) | (21.23) | (25.22) | [{"date":"2022-12-31","value":-2122.7,"profit":false},{"date":"2023-12-31","value":-2522.36,"profit":false}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
OKUR | |
---|---|
Current Ratio | 1.83 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OKUR | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OKUR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 5.85 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -4.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OKUR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
EV/R | 0.00 |
EV/Ebitda | NM |
OnKure Therapeutics, Inc. (OKUR) share price today is $15.625
Yes, Indians can buy shares of OnKure Therapeutics, Inc. (OKUR) on Vested. To buy OnKure Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OKUR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of OnKure Therapeutics, Inc. (OKUR) via the Vested app. You can start investing in OnKure Therapeutics, Inc. (OKUR) with a minimum investment of $1.
You can invest in shares of OnKure Therapeutics, Inc. (OKUR) via Vested in three simple steps:
The 52-week high price of OnKure Therapeutics, Inc. (OKUR) is $77.6. The 52-week low price of OnKure Therapeutics, Inc. (OKUR) is $9.8.
The price-to-earnings (P/E) ratio of OnKure Therapeutics, Inc. (OKUR) is
The price-to-book (P/B) ratio of OnKure Therapeutics, Inc. (OKUR) is 0.00
The dividend yield of OnKure Therapeutics, Inc. (OKUR) is 0.00%
The market capitalization of OnKure Therapeutics, Inc. (OKUR) is
The stock symbol (or ticker) of OnKure Therapeutics, Inc. is OKUR